Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Does Venetoclax Cause Vitiligo?

Sujatha Baddam, MD, Jorge Diaz Castro, MD

Blood (2019) 134 (Supplement_1): 5139.

https://doi.org/10.1182/blood-2019-130854

Published: 2019

Journal Articles

Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial

Othman Al-Sawaf, MD, Anna-Maria Fink, MD, Sandra Robrecht, PhD, Arijit Sinha, PhD, Maneesh Tandon, MD, Barbara F. Eichhorst, MD, Kirsten Fischer, MD, Michael Hallek, MD

Blood (2019) 134 (Supplement_1): 4315.

https://doi.org/10.1182/blood-2019-126570

Published: 2019

Journal Articles

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies

Jacqueline S Garcia, MD, Helen I. Gandler, Geoffrey Fell, MS, Ashlee J. Fiore, Donna S Neuberg, ScD, Adrienne Anderson, Kelsey O'Day, Marlise Luskin, MDMS, Martha Wadleigh, MD, Eric S. Winer, MD, Ilene Galinsky, Daniel J. DeAngelo, MD, David A. Frank, MD PhD, Richard M. Stone, MD

Blood (2019) 134 (Supplement_1): 2549.

https://doi.org/10.1182/blood-2019-126224

Published: 2019

Journal Articles

Serum Electrolyte Dynamics in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Apoorva Anandan, MD, Pingfu Fu, Merle Kolk, Nicole Ferrari, Arash Rashidi, MD, Melissa Copley, PharmD, James Driscoll, MD PhD, Paolo Caimi, MD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 5646.

https://doi.org/10.1182/blood-2019-122057

Published: 2019

Journal Articles

In-Hospital Complications and Outcomes of Autologous Stem Cell Transplantation in Multiple Myeloma Patients Older Than 65-Years Old in the United States: National Inpatient Sample Analysis, 2011-2015

Veli Bakalov, MD, Amy Tang, PhD, Hira G. Shaikh, MD, Shrunjal Shah, MD, Zena Chahine, MD, Robert B. Kaplan, MDBS,BA, John Lister, MD, Santhosh Sadashiv, MD

Blood (2019) 134 (Supplement_1): 4764.

https://doi.org/10.1182/blood-2019-131472

Published: 2019

Journal Articles

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Blood (2019) 134 (Supplement_1): 831.

https://doi.org/10.1182/blood-2019-126065

Published: 2019

Journal Articles

Feasibility and Cost Analysis of Day 4 Granulocyte Colony-Stimulating Factor Mobilized Peripheral Blood Progenitor Cell Collection from HLA-Matched Sibling Donors

Laura F. Newell, MD, Rebekah Knight, Kelsea Shoop, Sara Murray, Rogelyn Kwock, NP, Carol Jacoby, NP, Susan Slater, NP, Bryon Allen, NP, Brad Cota, MBA, Peggy Appel, Rachel J. Cook, MD, Richard T. Maziarz, MD, Gabrielle Meyers, MD

Blood (2018) 132 (Supplement 1): 4558.

https://doi.org/10.1182/blood-2018-99-120342

Published: 2018

Journal Articles

Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Kami J. Maddocks, MD, Farrukh T. Awan, MD MS, Ying Huang, MA, MS, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MD MS, Samantha Jaglowski, MD MPH, Basem M. William, MRCP, MD, Kristie A. Blum, MD, Beth A. Christian, MD

Blood (2018) 132 (Supplement 1): 4185.

https://doi.org/10.1182/blood-2018-99-117172

Published: 2018

Journal Articles

Risk Factors for the Development of Cardiac Arrhythmias during Hematopoietic Stem Cell Transplantation

Christopher Kapolas, PharmD, Jane Kosirog-Glowacki, PharmD, Kathryn L Barney, NP, Linda Advincula, NP, Leonard M. Klein, MD, Jacob D. Bitran, MD, Shams Bufalino, Tulio E Rodriguez, MD

Blood (2018) 132 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2018-99-120189

Published: 2018

Journal Articles

Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL)

Blood (2018) 132 (Supplement 1): 3268.

https://doi.org/10.1182/blood-2018-99-119444

Published: 2018

Journal Articles

Predicting Induction Toxicity with 7+3: Analysis of SWOG Trial S1203

Megan Othus, PhD, Guillermo Garcia-Manero, MD, Frederick R. Appelbaum, MD, Harry P. Erba, MD PhD, Roland B. Walter, MDPhDMS

Blood (2018) 132 (Supplement 1): 1403.

https://doi.org/10.1182/blood-2018-99-117565

Published: 2018

Journal Articles

Consolidative High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients with Primary Central Nervous System (CNS) Lymphoma or Non-Hodgkin Lymphoma with CNS Involvement Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen

Patricia A. Young, MD, Daria Gaut, MD, Davis A. Kimaiyo, Jonathan A. Grotts, John P Chute, MD, Gary J. Schiller, MD, John M. Timmerman, MD, Sven de Vos, Herbert A. Eradat, MD MS

Blood (2018) 132 (Supplement 1): 4611.

https://doi.org/10.1182/blood-2018-99-117225

Published: 2018

Journal Articles

Long Acting Zoledronic Acid Treatment for Vertebral Fracture Prevention in Multipl Myeloma Patients with Osteoporosis

Murat Cinarsoy, Ahmet Kursad Gunes, Hilmi Erdem Gozden

Blood (2018) 132 (Supplement 1): 1954.

https://doi.org/10.1182/blood-2018-99-111133

Published: 2018

Journal Articles

Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Rita Assi, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Tapan Kadia, MD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, Nitin Jain, MD, Naval Daver, MD, Taisuke Uehara, Takashi Owa, PhD, Gautam Borthakur, MD

Blood (2017) 130 (Supplement 1): 1380.

https://doi.org/10.1182/blood.V130.Suppl_1.1380.1380

Published: 2017

Journal Articles

Recent Trends in the Incidence and Outcomes of Tumor Lysis Syndrome in Hematological Malignancies: Data from 2010-2014 National Inpatient Sample

Ranjan Pathak, MD, Smith Giri, MBBS, Madan Aryal, MD

Blood (2017) 130 (Supplement 1): 3390.

https://doi.org/10.1182/blood.V130.Suppl_1.3390.3390

Published: 2017

Journal Articles

Toxicity and Outcomes of Autologous Stem Cell Transplant in Multiple Myeloma Patients with Renal Insufficiency: An Institutional Comparison between Two Eras

Amanda Li, MD BSc, Eshetu G Atenafu, M.Sc., P.Stat, Rosanne St. Bernard, MD MSc, Esther Masih-Khan, PhD, Donna Reece, MD FRCP(C), Norman Anthony Franke, MD, Rodger Tiedemann, MBChB, PhD, Anca Prica, MD FRCP(C), Suzanne Trudel, MD FRCP(C), Vishal Kukreti, MD FRCP(C), Christine I Chen, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 4537.

https://doi.org/10.1182/blood.V130.Suppl_1.4537.4537

Published: 2017

Journal Articles

a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

Kami J. Maddocks, MD, Jonathon B. Cohen, MD, Ying Huang, MA, MS, Beth A Christian, MD, Don M Benson, MD PhD, Jeffrey Jones, MD MPH, Christopher Flowers, MD MS, Leonard T. Heffner, MD, Cynthia Jenkins, RN, Jennfer Sexton, MHA, CCRC, Alison Neal, MPH, Melissa Kives, MPH, Kristie A. Blum, MD

Blood (2016) 128 (22): 1776.

https://doi.org/10.1182/blood.V128.22.1776.1776

Published: 2016

Journal Articles

Fludarabine, Cyclophosphamide, Rituximab (FCR) and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) - Final Results of a Phase I/II Study

Mazyar Shadman, MD MPH, Ajay K Gopal, MD, Oliver Press, MD PhD, David G. Maloney, MD PhD, Raya Mawad, MD, Troy Wadsworth, MD, Trevor W. Dennie, MD, Karl Schultheiss, MD, Kiarash Kojouri, MD MPH, Britt E Kammerer, John M. Pagel, MD PhD

Blood (2016) 128 (22): 4396.

https://doi.org/10.1182/blood.V128.22.4396.4396

Published: 2016

Journal Articles

Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium

Michael J. Burke, MD, Patrick Brown, MD, Richard Sposto, PhD, Lia Gore, MD, Alan S. Wayne, MD

Blood (2016) 128 (22): 2781.

https://doi.org/10.1182/blood.V128.22.2781.2781

Published: 2016

Journal Articles

Panobinostat-Augmented Cytarabine and Daunorubicin (7+3) Induction for Older Patients with AML or High-Risk MDS Is Well Tolerated and Results in Favorable Clinical Outcomes: The Panda Trial

Matthew J. Wieduwilt, MD PhD, Scott Thomas, PhD, Rebecca L. Olin, MD MSCE, Aaron C. Logan, MDPhD, Lloyd E. Damon, MD, Thomas G. Martin, III, MD, McNancy Kang, Peter H. Sayre, MD PhD, Wanda Boyer, NP,MSN, Karin ML Gaensler, MD, Kirsten Anderson, Pamela Munster, MD, Charalambos Andreadis, MD MSCE

Blood (2015) 126 (23): 1337.

https://doi.org/10.1182/blood.V126.23.1337.1337

Published: 2015

NARROW

Does Venetoclax Cause Vitiligo?

Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies

Serum Electrolyte Dynamics in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

In-Hospital Complications and Outcomes of Autologous Stem Cell Transplantation in Multiple Myeloma Patients Older Than 65-Years Old in the United States: National Inpatient Sample Analysis, 2011-2015

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Feasibility and Cost Analysis of Day 4 Granulocyte Colony-Stimulating Factor Mobilized Peripheral Blood Progenitor Cell Collection from HLA-Matched Sibling Donors

Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Risk Factors for the Development of Cardiac Arrhythmias during Hematopoietic Stem Cell Transplantation

Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL)

Predicting Induction Toxicity with 7+3: Analysis of SWOG Trial S1203

Consolidative High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients with Primary Central Nervous System (CNS) Lymphoma or Non-Hodgkin Lymphoma with CNS Involvement Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen

Long Acting Zoledronic Acid Treatment for Vertebral Fracture Prevention in Multipl Myeloma Patients with Osteoporosis

Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Recent Trends in the Incidence and Outcomes of Tumor Lysis Syndrome in Hematological Malignancies: Data from 2010-2014 National Inpatient Sample

Toxicity and Outcomes of Autologous Stem Cell Transplant in Multiple Myeloma Patients with Renal Insufficiency: An Institutional Comparison between Two Eras

a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

Fludarabine, Cyclophosphamide, Rituximab (FCR) and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) - Final Results of a Phase I/II Study

Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium

Panobinostat-Augmented Cytarabine and Daunorubicin (7+3) Induction for Older Patients with AML or High-Risk MDS Is Well Tolerated and Results in Favorable Clinical Outcomes: The Panda Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only